{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T01:21:49Z","timestamp":1780449709197,"version":"3.54.1"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,9,27]],"date-time":"2024-09-27T00:00:00Z","timestamp":1727395200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2024,9,27]],"date-time":"2024-09-27T00:00:00Z","timestamp":1727395200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Pharmacol Toxicol"],"DOI":"10.1186\/s40360-024-00790-2","type":"journal-article","created":{"date-parts":[[2024,9,27]],"date-time":"2024-09-27T12:02:35Z","timestamp":1727438555000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Safety assessment of Tafamidis: a real-world pharmacovigilance study of FDA adverse event reporting system (FAERS) events"],"prefix":"10.1186","volume":"25","author":[{"given":"Yidan","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shengzhu","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongyun","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leiyong","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Peng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,9,27]]},"reference":[{"issue":"3","key":"790_CR1","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1111\/joim.13169","volume":"289","author":"E Muchtar","year":"2021","unstructured":"Muchtar E, Dispenzieri A, Magen H, Grogan M, Mauermann M, McPhail ED, et al. Systemic amyloidosis from a (aa) to t (attr): a review. J Intern Med. 2021;289(3):268\u201392. https:\/\/doi.org\/10.1111\/joim.13169.","journal-title":"J Intern Med"},{"issue":"1","key":"790_CR2","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s40120-016-0040-x","volume":"5","author":"T Coelho","year":"2016","unstructured":"Coelho T, Merlini G, Bulawa CE, Fleming JA, Judge DP, Kelly JW, et al. Mechanism of action and clinical application of tafamidis in hereditary transthyretin amyloidosis. Neurol Ther. 2016;5(1):1\u201325. https:\/\/doi.org\/10.1007\/s40120-016-0040-x.","journal-title":"Neurol Ther"},{"key":"790_CR3","doi-asserted-by":"publisher","first-page":"1225","DOI":"10.2147\/DDDT.S289772","volume":"15","author":"A Burton","year":"2021","unstructured":"Burton A, Casta\u00f1o A, Bruno M, Riley S, Schumacher J, Sultan MB, et al. Drug discovery and development in rare diseases: taking a closer look at the tafamidis story. Drug Des Devel Ther. 2021;15:1225\u201343. https:\/\/doi.org\/10.2147\/DDDT.S289772.","journal-title":"Drug Des Devel Ther"},{"key":"790_CR4","doi-asserted-by":"publisher","unstructured":"Ney S, Gertz RJ, Pennig L, Nies RJ, Holtick U, V\u00f6lker LA, et al. Multiparametric monitoring of disease progression in contemporary patients with wild-type transthyretin amyloid cardiomyopathy initiating tafamidis treatment. J Clin Med. 2024;13(1). https:\/\/doi.org\/10.3390\/jcm13010284.","DOI":"10.3390\/jcm13010284"},{"issue":"8","key":"790_CR5","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1007\/s40265-019-01129-6","volume":"79","author":"YN Lamb","year":"2019","unstructured":"Lamb YN, Deeks ED. Tafamidis: a review in transthyretin amyloidosis with polyneuropathy. Drugs. 2019;79(8):863\u201374. https:\/\/doi.org\/10.1007\/s40265-019-01129-6.","journal-title":"Drugs"},{"issue":"11","key":"790_CR6","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1056\/NEJMoa1805689","volume":"379","author":"MS Maurer","year":"2018","unstructured":"Maurer MS, Schwartz JH, Gundapaneni B, Elliott PM, Merlini G, Waddington-Cruz M, et al. Tafamidis treatment for patients with transthyretin amyloid cardiomyopathy. N Engl J Med. 2018;379(11):1007\u201316. https:\/\/doi.org\/10.1056\/NEJMoa1805689.","journal-title":"N Engl J Med"},{"issue":"4","key":"790_CR7","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1080\/13506129.2019.1643714","volume":"26","author":"P Huber","year":"2019","unstructured":"Huber P, Flynn A, Sultan MB, Li H, Rill D, Ebede B, et al. A comprehensive safety profile of tafamidis in patients with transthyretin amyloid polyneuropathy. Amyloid. 2019;26(4):203\u201309. https:\/\/doi.org\/10.1080\/13506129.2019.1643714.","journal-title":"Amyloid: Int J Experimental Clin Invest: Official J Int Soc Amyloidosis"},{"issue":"1","key":"790_CR8","doi-asserted-by":"publisher","first-page":"e008193","DOI":"10.1161\/CIRCHEARTFAILURE.120.008193","volume":"15","author":"P Elliott","year":"2022","unstructured":"Elliott P, Drachman BM, Gottlieb SS, Hoffman JE, Hummel SL, Lenihan DJ, et al. Long-term survival with tafamidis in patients with transthyretin amyloid cardiomyopathy. Circ Heart Fail. 2022;15(1):e008193. https:\/\/doi.org\/10.1161\/CIRCHEARTFAILURE.120.008193.","journal-title":"Circ Heart Fail"},{"issue":"4","key":"790_CR9","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1007\/s40264-019-00899-y","volume":"43","author":"U Vogel","year":"2020","unstructured":"Vogel U, van Stekelenborg J, Dreyfus B, Garg A, Habib M, Hosain R, et al. Investigating overlap in signals from evdas, faers, and vigibase(\u00ae). Drug Saf. 2020;43(4):351\u201362. https:\/\/doi.org\/10.1007\/s40264-019-00899-y.","journal-title":"Drug Saf"},{"issue":"6","key":"790_CR10","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1111\/j.1365-2125.2011.04037.x","volume":"72","author":"J Montastruc","year":"2011","unstructured":"Montastruc J, Sommet A, Bagheri H, Lapeyre-Mestre M. Benefits and strengths of the disproportionality analysis for identification of adverse drug reactions in a pharmacovigilance database. Br J Clin Pharmacol. 2011;72(6):905\u201308. https:\/\/doi.org\/10.1111\/j.1365-2125.2011.04037.x.","journal-title":"Br J Clin Pharmacol"},{"issue":"8","key":"790_CR11","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1002\/pds.1001","volume":"13","author":"KJ Rothman","year":"2004","unstructured":"Rothman KJ, Lanes S, Sacks ST. The reporting odds ratio and its advantages over the proportional reporting ratio. Pharmacoepidemiol Drug Saf. 2004;13(8):519\u201323.","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"6","key":"790_CR12","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1002\/pds.677","volume":"10","author":"SJ Evans","year":"2001","unstructured":"Evans SJ, Waller PC, Davis S. Use of proportional reporting ratios (prrs) for signal generation from spontaneous adverse drug reaction reports. Pharmacoepidemiol Drug Saf. 2001;10(6):483\u201386.","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"3","key":"790_CR13","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1080\/00031305.1999.10474456","volume":"53","author":"W Dumouchel","year":"1999","unstructured":"Dumouchel W. Bayesian data mining in large frequency tables, with an application to the fda spontaneous reporting system. Am Stat. 1999;53(3):177\u201390. https:\/\/doi.org\/10.1080\/00031305.1999.10474456.","journal-title":"Am Stat"},{"issue":"4","key":"790_CR14","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1007\/s002280050466","volume":"54","author":"A Bate","year":"1998","unstructured":"Bate A, Lindquist M, Edwards IR, Olsson S, Orre R, Lansner A, et al. A bayesian neural network method for adverse drug reaction signal generation. Eur J Clin Pharmacol. 1998;54(4):315\u201321.","journal-title":"Eur J Clin Pharmacol"},{"key":"790_CR15","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1016\/j.jad.2023.11.025","volume":"346","author":"Y Jiang","year":"2024","unstructured":"Jiang Y, Zhou L, Shen Y, Zhou Q, Ji Y, Zhu H. Safety assessment of brexpiprazole: real-world adverse event analysis from the faers database. J Affect Disord. 2024;346:223\u201329. https:\/\/doi.org\/10.1016\/j.jad.2023.11.025.","journal-title":"J Affect Disord"},{"key":"790_CR16","doi-asserted-by":"publisher","first-page":"970066","DOI":"10.3389\/fphar.2022.970066","volume":"13","author":"S Tang","year":"2022","unstructured":"Tang S, Wu Z, Xu L, Wen Q, Zhang X. Adverse reaction signals mining and hemorrhagic signals comparison of ticagrelor and clopidogrel: a pharmacovigilance study based on faers. Front Pharmacol. 2022;13:970066. https:\/\/doi.org\/10.3389\/fphar.2022.970066.","journal-title":"Front Pharmacol"},{"issue":"2","key":"790_CR17","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1016\/j.jacc.2016.03.596","volume":"68","author":"MS Maurer","year":"2016","unstructured":"Maurer MS, Hanna M, Grogan M, Dispenzieri A, Witteles R, Drachman B, et al. Genotype and phenotype of transthyretin cardiac amyloidosis: thaos (transthyretin amyloid outcome survey). J Am Coll Cardiol. 2016;68(2):161\u201372. https:\/\/doi.org\/10.1016\/j.jacc.2016.03.596.","journal-title":"J Am Coll Cardiol"},{"issue":"18","key":"790_CR18","doi-asserted-by":"publisher","first-page":"3517","DOI":"10.1093\/cvr\/cvac119","volume":"118","author":"A Porcari","year":"2023","unstructured":"Porcari A, Fontana M, Gillmore JD. Transthyretin cardiac amyloidosis. Cardiovasc Res. 2023;118(18):3517\u201335. https:\/\/doi.org\/10.1093\/cvr\/cvac119.","journal-title":"Cardiovasc Res"},{"issue":"10","key":"790_CR19","doi-asserted-by":"publisher","first-page":"736","DOI":"10.1016\/j.jchf.2021.05.005","volume":"9","author":"AG Caponetti","year":"2021","unstructured":"Caponetti AG, Rapezzi C, Gagliardi C, Milandri A, Dispenzieri A, Kristen AV, et al. Sex-related risk of cardiac involvement in hereditary transthyretin amyloidosis: insights from thaos. Jacc Heart Fail. 2021;9(10):736\u201346. https:\/\/doi.org\/10.1016\/j.jchf.2021.05.005.","journal-title":"Jacc Heart Fail"},{"issue":"3","key":"790_CR20","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1007\/s40119-022-00265-7","volume":"11","author":"CM Campbell","year":"2022","unstructured":"Campbell CM, LoRusso S, Dispenzieri A, Kristen AV, Maurer MS, Rapezzi C, et al. Sex differences in wild-type transthyretin amyloidosis: an analysis from the transthyretin amyloidosis outcomes survey (thaos). Cardiol Ther. 2022;11(3):393\u2013405. https:\/\/doi.org\/10.1007\/s40119-022-00265-7.","journal-title":"Cardiol Ther"},{"issue":"21","key":"790_CR21","doi-asserted-by":"publisher","first-page":"2451","DOI":"10.1016\/j.jacc.2015.09.075","volume":"66","author":"MA Gertz","year":"2015","unstructured":"Gertz MA, Benson MD, Dyck PJ, Grogan M, Coelho T, Cruz M, et al. Diagnosis, prognosis, and therapy of transthyretin amyloidosis. J Am Coll Cardiol. 2015;66(21):2451\u201366. https:\/\/doi.org\/10.1016\/j.jacc.2015.09.075.","journal-title":"J Am Coll Cardiol"},{"issue":"9","key":"790_CR22","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1016\/j.recesp.2011.05.003","volume":"64","author":"P Garc\u00eda-Pav\u00eda","year":"2011","unstructured":"Garc\u00eda-Pav\u00eda P, Tom\u00e9-Esteban MT, Rapezzi C. [Amyloidosis. Also a heart disease]. Rev Esp Cardiol. 2011;64(9):797\u2013808. https:\/\/doi.org\/10.1016\/j.recesp.2011.05.003.","journal-title":"Rev Esp Cardiol"},{"issue":"1\u20132","key":"790_CR23","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1007\/s11010-008-9841-2","volume":"317","author":"I Gon\u00e7alves","year":"2008","unstructured":"Gon\u00e7alves I, Alves CH, Quintela T, Baltazar G, Socorro S, Saraiva MJ, et al. Transthyretin is up-regulated by sex hormones in mice liver. Mol Cell Biochem. 2008;317(1\u20132):137\u201342. https:\/\/doi.org\/10.1007\/s11010-008-9841-2.","journal-title":"Mol Cell Biochem"},{"issue":"23","key":"790_CR24","doi-asserted-by":"publisher","first-page":"1826","DOI":"10.1093\/eurheartj\/ehv583","volume":"37","author":"T Damy","year":"2016","unstructured":"Damy T, Costes B, Hag\u00e8ge AA, Donal E, Eicher J, Slama M, et al. Prevalence and clinical phenotype of hereditary transthyretin amyloid cardiomyopathy in patients with increased left ventricular wall thickness. Eur Heart J. 2016;37(23):1826\u201334. https:\/\/doi.org\/10.1093\/eurheartj\/ehv583.","journal-title":"Eur Heart J"},{"issue":"10","key":"790_CR25","doi-asserted-by":"publisher","first-page":"1014","DOI":"10.1016\/j.jacc.2016.06.033","volume":"68","author":"M Grogan","year":"2016","unstructured":"Grogan M, Scott CG, Kyle RA, Zeldenrust SR, Gertz MA, Lin G, et al. Natural history of wild-type transthyretin cardiac amyloidosis and risk stratification using a novel staging system. J Am Coll Cardiol. 2016;68(10):1014\u201320. https:\/\/doi.org\/10.1016\/j.jacc.2016.06.033.","journal-title":"J Am Coll Cardiol"},{"issue":"4","key":"790_CR26","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1111\/j.1532-5415.2011.03868.x","volume":"60","author":"K Dharmarajan","year":"2012","unstructured":"Dharmarajan K, Maurer MS. Transthyretin cardiac amyloidoses in older North americans. J Am Geriatr Soc. 2012;60(4):765\u201374. https:\/\/doi.org\/10.1111\/j.1532-5415.2011.03868.x.","journal-title":"J Am Geriatr Soc"},{"issue":"3","key":"790_CR27","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1161\/CIRCULATIONAHA.115.018852","volume":"133","author":"LH Connors","year":"2016","unstructured":"Connors LH, Sam F, Skinner M, Salinaro F, Sun F, Ruberg FL, et al. Heart failure resulting from age-related cardiac amyloid disease associated with wild-type transthyretin: a prospective, observational cohort study. Circulation. 2016;133(3):282\u201390. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.115.018852.","journal-title":"Circulation"},{"issue":"2","key":"790_CR28","doi-asserted-by":"publisher","first-page":"229","DOI":"10.2217\/ahe.13.10","volume":"9","author":"RC Givens","year":"2013","unstructured":"Givens RC, Russo C, Green P, Maurer MS. Comparison of cardiac amyloidosis due to wild-type and v122i transthyretin in older adults referred to an academic medical center. Aging Health. 2013;9(2):229\u201335.","journal-title":"Aging Health"},{"issue":"3","key":"790_CR29","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1097\/CRD.0000000000000306","volume":"28","author":"JJ Nawarskas","year":"2020","unstructured":"Nawarskas JJ, Shephard EA. Tafamidis: a novel treatment for transthyretin amyloid cardiomyopathy. Cardiol Rev. 2020;28(3):156\u201360. https:\/\/doi.org\/10.1097\/CRD.0000000000000306.","journal-title":"Cardiol Rev"},{"issue":"1","key":"790_CR30","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1161\/CIRCULATIONAHA.118.038169","volume":"140","author":"T Lane","year":"2019","unstructured":"Lane T, Fontana M, Martinez-Naharro A, Quarta CC, Whelan CJ, Petrie A, et al. Natural history, quality of life, and outcome in cardiac transthyretin amyloidosis. Circulation. 2019;140(1):16\u201326. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.118.038169.","journal-title":"Circulation"},{"issue":"10","key":"790_CR31","doi-asserted-by":"publisher","first-page":"1286","DOI":"10.1161\/CIRCULATIONAHA.111.078915","volume":"126","author":"FL Ruberg","year":"2012","unstructured":"Ruberg FL, Berk JL. Transthyretin (ttr) cardiac amyloidosis. Circulation. 2012;126(10):1286\u2013300. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.111.078915.","journal-title":"Circulation"},{"issue":"1","key":"790_CR32","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1097\/MS9.0000000000001482","volume":"86","author":"M Sukaina","year":"2024","unstructured":"Sukaina M, Rehman S, Waheed M, Shehryar M, Rasool R, Ahmed N, et al. Efficacy of tafamidis in transthyretin amyloid cardiomyopathy: a systematic review and meta-analysis. Annals Med Surg (2012). 2024;86(1):433\u201338. https:\/\/doi.org\/10.1097\/MS9.0000000000001482.","journal-title":"Annals Med Surg (2012)"},{"issue":"9","key":"790_CR33","doi-asserted-by":"publisher","first-page":"e18221","DOI":"10.7759\/cureus.18221","volume":"13","author":"BM Singh","year":"2021","unstructured":"Singh BM, Bohara N, Gautam K, Basnet M, Kc S, Kc B, et al. A systematic review of tafamidis in patients with transthyretin amyloid cardiomyopathy. Cureus. 2021;13(9):e18221. https:\/\/doi.org\/10.7759\/cureus.18221.","journal-title":"Cureus"},{"issue":"1","key":"790_CR34","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1007\/s10162-002-2058-2","volume":"4","author":"T Klockars","year":"2003","unstructured":"Klockars T, Perheentupa T, Dahl HM. In silico analyses of mouse inner-ear transcripts. J Assoc Res Otolaryngology. 2003;4(1):24\u201340.","journal-title":"J Association Res Otolaryngology: Jaro"},{"issue":"4","key":"790_CR35","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1080\/13506129.2019.1663814","volume":"26","author":"S Bartier","year":"2019","unstructured":"Bartier S, Bodez D, Kharoubi M, Guellich A, Canou\u00ef-Poitrine F, Chatelin V, et al. Association between hearing loss and hereditary attr amyloidosis. Amyloid. 2019;26(4):234\u201342. https:\/\/doi.org\/10.1080\/13506129.2019.1663814.","journal-title":"Amyloid: Int J Experimental Clin Invest: Official J Int Soc Amyloidosis"},{"issue":"3","key":"790_CR36","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1080\/13506129.2017.1357545","volume":"24","author":"FA Barroso","year":"2017","unstructured":"Barroso FA, Judge DP, Ebede B, Li H, Stewart M, Amass L, et al. Long-term safety and efficacy of tafamidis for the treatment of hereditary transthyretin amyloid polyneuropathy: results up to 6 years. Amyloid. 2017;24(3):194\u2013204. https:\/\/doi.org\/10.1080\/13506129.2017.1357545.","journal-title":"Amyloid: Int J Experimental Clin Invest: Official J Int Soc Amyloidosis"},{"issue":"2","key":"790_CR37","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1017\/S0954422413000061","volume":"26","author":"A Melse-Boonstra","year":"2013","unstructured":"Melse-Boonstra A, Mackenzie I. Iodine deficiency, thyroid function and hearing deficit: a review. Nutr Res Rev. 2013;26(2):110\u201317. https:\/\/doi.org\/10.1017\/S0954422413000061.","journal-title":"Nutr Res Rev"},{"issue":"7","key":"790_CR38","doi-asserted-by":"publisher","first-page":"652","DOI":"10.3760\/cma.j.cn115330-20191212-00756","volume":"55","author":"L Chen","year":"2020","unstructured":"Chen L, Wang YJ, Sun X, Zhang N, Li YN, Fan ZM, et al. [Analysis of prognostic factors of low-frequency type of sudden sensorineural hearing loss]. Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi = Chin J Otorhinolaryngol Head Neck Surg. 2020;55(7):652\u201357. https:\/\/doi.org\/10.3760\/cma.j.cn115330-20191212-00756.","journal-title":"Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi = Chin J Otorhinolaryngol Head Neck Surg"},{"issue":"3","key":"790_CR39","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1007\/s40264-013-0018-x","volume":"36","author":"PM Coloma","year":"2013","unstructured":"Coloma PM, Trifir\u00f2 G, Patadia V, Sturkenboom M. Postmarketing safety surveillance: where does signal detection using electronic healthcare records fit into the big picture? Drug Saf. 2013;36(3):183\u201397. https:\/\/doi.org\/10.1007\/s40264-013-0018-x.","journal-title":"Drug Saf"},{"issue":"5","key":"790_CR40","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1093\/bib\/bbx010","volume":"19","author":"S Vilar","year":"2018","unstructured":"Vilar S, Friedman C, Hripcsak G. Detection of drug-drug interactions through data mining studies using clinical sources, scientific literature and social media. Brief Bioinform. 2018;19(5):863\u201377. https:\/\/doi.org\/10.1093\/bib\/bbx010.","journal-title":"Brief Bioinform"},{"key":"790_CR41","doi-asserted-by":"publisher","unstructured":"Shi X, Cheng Q, Zhao Y, Zou S, Sun M. A real-world pharmacovigilance study of abaloparatide based on the fda adverse event reporting system (faers). Osteoporos Int. 2023;34(12):2047-58. https:\/\/doi.org\/10.1007\/s00198-023-06877-6","DOI":"10.1007\/s00198-023-06877-6"},{"key":"790_CR42","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.jad.2023.11.076","volume":"347","author":"H Zhu","year":"2024","unstructured":"Zhu H, Qu Y, Du Z, Zhou Q, Shen Y, Jiang Y, et al. Mining and analysis of adverse event signals of cariprazine based on the real-world data of faers database. J Affect Disord. 2024;347:45\u201350. https:\/\/doi.org\/10.1016\/j.jad.2023.11.076.","journal-title":"J Affect Disord"}],"container-title":["BMC Pharmacology and Toxicology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40360-024-00790-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40360-024-00790-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40360-024-00790-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,27]],"date-time":"2024-09-27T12:06:50Z","timestamp":1727438810000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcpharmacoltoxicol.biomedcentral.com\/articles\/10.1186\/s40360-024-00790-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,27]]},"references-count":42,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["790"],"URL":"https:\/\/doi.org\/10.1186\/s40360-024-00790-2","relation":{},"ISSN":["2050-6511"],"issn-type":[{"value":"2050-6511","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,9,27]]},"assertion":[{"value":"25 May 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 September 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 September 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable. This study was deemed non-human subject related research.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"71"}}